Introduction
Jounce Therapeutics (JNCE) is a clinical-stage immunotherapy company developing therapies that enable the immune system to attack tumors. The company has developed a suite of integrated technologies that comprise their Translational Science Platform, enabling them to comprehensively interrogate the cellular and molecular composition of tumors.
The company uses a biomarker-drive approach from discovery all the way through clinical development. Their translational Science Platform is leveraged to identify and prioritize targets across a broad spectrum of immune and non-immune cell types. Subsequently, in the early development process, potential predictive biomarkers are identified to